Please try another search
Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It’s XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company’s product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase III clinical trial; and LYR-220 for CRS patients with and without nasal polyps. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.
Name | Age | Since | Title |
---|---|---|---|
W. Bradford Smith | 66 | 2019 | Independent Director |
Gary M. Ansel | - | - | Member of Medical Advisory Board |
Martin Schillinger | - | - | Member of Medical Advisory Board |
I. Baumgartner | - | - | Member of Medical Advisory Board |
Robert S. Langer | 73 | 2006 | Member of Scientific Advisory Board |
George M. Whitesides | 83 | 2006 | Member of Scientific Advisory Board |
Michael D. Dake | - | - | Member of Medical Advisory Board |
William A. Gray | - | - | Member of Medical Advisory Board |
James Morley Anderson | 81 | - | Member of Scientific Advisory Board |
Mahmood K. Razavi | - | - | Member of Medical Advisory Board |
James R. Tobin | 77 | 2022 | Lead Independent Director |
Maria Palasis | 58 | 2015 | CEO, President & Director |
Harlan W. Waksal | 70 | 2022 | Executive Chairman |
C. Ann Merrifield | 72 | 2019 | Independent Director |
Robert S. Schwartz | - | - | Member of Scientific Advisory Board |
Nancy L. Snyderman | 71 | 2020 | Independent Director |
Michael Seth Altman | 42 | 2018 | Independent Director |
Konstantin Poukalov | 40 | 2020 | Independent Director |
Stephen L. Hilbert | - | - | Member of Scientific Advisory Board |
Renu Virmani | - | - | Member of Scientific Advisory Board |
Mark Saltzman | - | - | Member of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review